Monopar Therapeutics (MNPR) Cash & Equivalents (2016 - 2020)
Historic Cash & Equivalents for Monopar Therapeutics (MNPR) over the last 5 years, with Q3 2020 value amounting to $18.0 million.
- Monopar Therapeutics' Cash & Equivalents rose 30010.04% to $18.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was $18.0 million, marking a year-over-year increase of 30010.04%. This contributed to the annual value of $13.2 million for FY2019, which is 9170.7% up from last year.
- Latest data reveals that Monopar Therapeutics reported Cash & Equivalents of $18.0 million as of Q3 2020, which was up 30010.04% from $12.5 million recorded in Q2 2020.
- Monopar Therapeutics' Cash & Equivalents' 5-year high stood at $18.0 million during Q3 2020, with a 5-year trough of $2.9 million in Q4 2016.
- In the last 5 years, Monopar Therapeutics' Cash & Equivalents had a median value of $7.9 million in 2018 and averaged $8.4 million.
- In the last 5 years, Monopar Therapeutics' Cash & Equivalents crashed by 4100.31% in 2019 and then skyrocketed by 30010.04% in 2020.
- Over the past 5 years, Monopar Therapeutics' Cash & Equivalents (Quarter) stood at $2.9 million in 2016, then surged by 240.48% to $9.8 million in 2017, then fell by 29.54% to $6.9 million in 2018, then surged by 91.71% to $13.2 million in 2019, then soared by 36.09% to $18.0 million in 2020.
- Its Cash & Equivalents was $18.0 million in Q3 2020, compared to $12.5 million in Q2 2020 and $12.6 million in Q1 2020.